Kadmon Initiates Placebo-Controlled Phase 2 Clinical Trial Evaluating KD025 in Psoriasis
NEW YORK--(BUSINESS WIRE)--
Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the first patient
has been dosed in a double-blind, placebo-controlled Phase 2 clinical
trial of KD025, the Company’s oral inhibitor of Rho-associated
coiled-coil kinase 2 (ROCK2), in moderate to severe chronic plaque
psoriasis. The dose-finding study examines KD025 administered at four
doses: 200 mg once daily (QD), 200 mg twice daily (BID), 400 mg QD and
600 mg QD (administered as 400 mg in the morning and 200 mg in the
evening) compared to matching placebo BID for 16 weeks in approximately
150 patients in the United States.
The study builds on results from a recently completed open-label Phase 2
clinical study of KD025 in moderate to severe psoriasis, in which 85% of
patients completing the trial achieved Psoriasis Area and Severity Index
(PASI) score reductions with minimal side effects. Of note, 71% of
patients receiving KD025 200 mg BID achieved at least a 50% decrease in
PASI score (PASI 50), and 42% of patients receiving KD025 400 mg QD and
achieved PASI 50. In addition, 84% of patients for whom measurements
were available showed reduced levels of pro-inflammatory cytokine IL-17,
the key driver in psoriasis, with minimal effect on the rest of the
immune system, potentially avoiding toxicities and increased
susceptibility to infections associated with currently available
“With its demonstrated safety and targeted anti-inflammatory activity,
we believe KD025 potentially offers a new approach to treating
psoriasis, while preserving normal immune function,” said Harlan W.
Waksal, M.D., President and Chief Executive Officer of Kadmon. “We are
optimistic that data from our placebo-controlled trial will provide
further evidence of the potential value of KD025 as a psoriasis therapy.”
In addition to psoriasis, Kadmon is conducting Phase 2 clinical trials
of KD025 in chronic graft-versus-host disease and in idiopathic
pulmonary fibrosis, diseases in which ROCK2 signaling is up-regulated.
About Kadmon Holdings, Inc.
Kadmon Holdings, Inc. is a fully integrated biopharmaceutical company
focused on developing innovative products for significant unmet medical
needs. We have a diversified product pipeline in autoimmune and fibrotic
diseases, oncology and genetic diseases.
Safe Harbor Statement
This press release contains forward-looking statements. Such statements
may be preceded by the words "may," "will," "should," "expects,"
"plans," "anticipates," "could," "intends," "targets," "projects,"
"contemplates," "believes," "estimates," "predicts," "potential" or
"continue" or the negative of these terms or other similar expressions.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by the
forward-looking statements. We believe that these factors include, but
are not limited to, (i) the initiation, timing, progress and results of
our preclinical studies and clinical trials, and our research and
development programs; (ii) our ability to advance product candidates
into, and successfully complete, clinical trials; (iii) our reliance on
the success of our product candidates; (iv) the timing or likelihood of
regulatory filings and approvals; (v) our ability to expand our sales
and marketing capabilities; (vi) the commercialization of our product
candidates, if approved; (vii) the pricing and reimbursement of our
product candidates, if approved; (viii) the implementation of our
business model, strategic plans for our business, product candidates and
technology; (ix) the scope of protection we are able to establish and
maintain for intellectual property rights covering our product
candidates and technology; (x) our ability to operate our business
without infringing the intellectual property rights and proprietary
technology of third parties; (xi) costs associated with defending
intellectual property infringement, product liability and other claims;
(xii) regulatory developments in the United States, Europe and other
jurisdictions; (xiii) estimates of our expenses, future revenues,
capital requirements and our needs for additional financing; (xiv) the
potential benefits of strategic collaboration agreements and our ability
to enter into strategic arrangements; (xv) our ability to maintain and
establish collaborations or obtain additional grant funding; (xvi) the
rate and degree of market acceptance of our product candidates; (xvii)
developments relating to our competitors and our industry, including
competing therapies; (xviii) our ability to effectively manage our
anticipated growth; and (xix) our ability to attract and retain
qualified employees and key personnel. More detailed information about
Kadmon and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company's filings with
the U.S. Securities and Exchange Commission (SEC), including the
Company's prospectus filed pursuant to Rule 424(b) under the Securities
Act of 1933, as amended, with the SEC on July 27, 2016. Investors and
security holders are urged to read these documents free of charge on the
SEC's web site at www.sec.gov.
The Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future events
View source version on businesswire.com: http://www.businesswire.com/news/home/20160921006538/en/
Kadmon Holdings, Inc.
Source: Kadmon Holdings, Inc.